Foundation models for molecular diagnostics - machine learning with biological ‘common sense’
FoundationDX aims to enhance molecular diagnostics by using self-supervised learning on diverse biomolecular data to accurately predict cancer subtypes and treatment outcomes without extensive labeled datasets.
Projectdetails
Introduction
Molecular diagnostics is crucial in fulfilling the promise of personalized medicine. While we are amidst an AI revolution, current machine learning models (ML) struggle to effectively learn from molecular (‘omics’) patient profiles and fail to make robust predictions. Perhaps this is not a surprise. After all, molecular disease biology is immensely complex, and we ask ML models to predict such complicated things as patient prognosis, without them ‘knowing’ anything about molecular biology and based on limited training data.
Approach
To address this, I will create foundation models on top of the vast troves of available biomolecular data, such as:
- Multi-omics profiles in healthy and diseased tissues
- High-resolution single-cell data
- Biological knowledge graphs
This unique approach is driven by self-supervised learning (SSL), an important driver of AI, which offers the opportunity to learn a comprehensive representation of the multimodal biology of the cell – without the need for well-annotated patient data.
FoundationDX Model
Starting from this strong basis, the FoundationDX model can then reliably predict cancer subtype or prognosis as it no longer needs to start from scratch on too high-dimensional, too low sample-size datasets. Effectively, we give our systems biological ‘common sense’, foregoing the need for millions of labeled training samples. This uniquely enables us to address one of the most clinically relevant questions: which treatment is best for the patient?
Research Program
The FoundationDX research program is designed to deliver key insights into how the SSL revolution can be used to drive progress in the field of molecular diagnostics. It contains a ‘clinical-grade’ benchmarking module and solves three urgent diagnostic challenges, including:
- Noninvasive subtyping of pediatric brain cancer
- [Additional challenges can be listed here if needed]
- [Additional challenges can be listed here if needed]
The time for powerful, robust, and generalizable, knowledge-aware machine learning solutions to previously intractable molecular diagnostics problems has come. FoundationDX aims to deliver this.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.000.000 |
Totale projectbegroting | € 2.000.000 |
Tijdlijn
Startdatum | 1-5-2024 |
Einddatum | 30-4-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITAIR MEDISCH CENTRUM UTRECHTpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
New directions for deep learning in cancer research through concept explainability and virtual experimentation.NADIR aims to enhance deep learning in cancer research by integrating biological knowledge to extract concepts and verify mechanisms, focusing on tumor-immune interactions in colorectal and gastric cancer. | ERC Starting... | € 1.498.750 | 2024 | Details |
AI-based leukemia detection in routine diagnostic blood smear dataDevelop LeukoScreen, an AI software to enhance the speed and accuracy of acute promyelocytic leukemia diagnosis, improving patient outcomes and optimizing laboratory workflows. | ERC Proof of... | € 150.000 | 2023 | Details |
Learning and modeling the molecular response of single cells to drug perturbationsDeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings. | ERC Advanced... | € 2.497.298 | 2023 | Details |
Trustworthy AI tools for personalized oncologyThe project aims to develop trustworthy AI tools for personalized oncology to enhance diagnosis, outcome prediction, and treatment recommendations, ensuring reliability and transparency in clinical practice. | ERC Consolid... | € 1.999.225 | 2023 | Details |
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRIDevelop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics. | ERC Starting... | € 1.497.669 | 2024 | Details |
New directions for deep learning in cancer research through concept explainability and virtual experimentation.
NADIR aims to enhance deep learning in cancer research by integrating biological knowledge to extract concepts and verify mechanisms, focusing on tumor-immune interactions in colorectal and gastric cancer.
AI-based leukemia detection in routine diagnostic blood smear data
Develop LeukoScreen, an AI software to enhance the speed and accuracy of acute promyelocytic leukemia diagnosis, improving patient outcomes and optimizing laboratory workflows.
Learning and modeling the molecular response of single cells to drug perturbations
DeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings.
Trustworthy AI tools for personalized oncology
The project aims to develop trustworthy AI tools for personalized oncology to enhance diagnosis, outcome prediction, and treatment recommendations, ensuring reliability and transparency in clinical practice.
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI
Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancerQlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe. | EIC Accelerator | € 2.491.650 | 2024 | Details |
DETACT - Detection of Enzymes and muTAtions for Cancer TreatmentCytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen. | Mkb-innovati... | € 215.845 | 2019 | Details |
Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patientsDoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Uitbreiding methylatie platformsMLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling. | Mkb-innovati... | € 20.000 | 2021 | Details |
Ontwikkeling van innovatieve prognostische melanoomtestDit project ontwikkelt en valideert een innovatieve prognostische melanoomtest gebaseerd op methylatie van het LY75 gen voor bredere klinische toepassing. | Mkb-innovati... | € 165.130 | 2020 | Details |
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer
Qlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe.
DETACT - Detection of Enzymes and muTAtions for Cancer Treatment
Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.
Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients
DoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually.
Uitbreiding methylatie platforms
MLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling.
Ontwikkeling van innovatieve prognostische melanoomtest
Dit project ontwikkelt en valideert een innovatieve prognostische melanoomtest gebaseerd op methylatie van het LY75 gen voor bredere klinische toepassing.